Date of Report (Date of earliest event reported): May 13, 2026
TANGO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-39485
85-1195036
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
201 Brookline Ave., Suite 901
Boston, MA
02215
(Address of principal executive offices)
(Zip code)
Registrant’s telephone number, including area code: 857-320-4900
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b)under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c)under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common stock, par value $0.001
per share
TNGX
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition.
On May 13, 2026, Tango Therapeutics, Inc. (“Tango” or the “Company”) issued a press release relating to its results of operations and financial condition for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The press release, and the information set forth therein (including Exhibit 99.1), is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. Nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in the filing unless specifically stated so therein.
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b)
Resignation of Alexis Borisy
On May 12, 2026, Alexis Borisy resigned from the Company’s Board of Directors (the “Board”), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the “Compensation Committee”) and as a member thereof, in each case effective as of May 13, 2026. Mr. Borisy’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies.
Resignation of Kanishka Pothula
Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), in each case effective as of May 13, 2026. Mr. Pothula’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies.
In connection with Mr. Borisy’s and Mr. Pothula’s resignations from the Board, the Board appointed Sung Lee as Lead Independent Director of the Board and the Chairperson of the Compensation Committee and as a member thereof, each effective as of May 13, 2026. The Compensation Committee now consists of Sung Lee, John Ketchum and Mace Rothenberg, M.D. The Board also approved the appointment of Sung Lee as a member of the NCG Committee, effective as of May 13, 2026. The NCG Committee now consists of Mace Rothenberg, Sung Lee and Lesley Ann Calhoun.
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
